File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/hep.24000
- Scopus: eid_2-s2.0-78751552761
- PMID: 20979057
- WOS: WOS:000286406300018
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation
Title | Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation | ||||
---|---|---|---|---|---|
Authors | |||||
Issue Date | 2011 | ||||
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | ||||
Citation | Hepatology, 2011, v. 53 n. 1, p. 160-170 How to Cite? | ||||
Abstract | Liver tumor-initiating cells (T-ICs) are capable of self-renewal and tumor initiation and are more chemoresistant to chemotherapeutic drugs. The current therapeutic strategies for targeting stem cell self-renewal pathways therefore represent rational approaches for cancer prevention and treatment. In the present study, we found that Lup-20(29)-en-3β-ol (lupeol), a triterpene found in fruits and vegetables, inhibited the self-renewal ability of liver T-ICs present in both hepatocellular carcinoma (HCC) cell lines and clinical HCC samples, as reflected by hepatosphere formation. Furthermore, lupeol inhibited in vivo tumorigenicity in nude mice and down-regulated CD133 expression, which was previously shown to be a T-IC marker for HCC. In addition, lupeol sensitized HCC cells to chemotherapeutic agents through the phosphatase and tensin homolog (PTEN)-Akt-ABCG2 pathway. PTEN plays a crucial role in the self-renewal and chemoresistance of liver T-ICs; down-regulation of PTEN by a lentiviral-based approach reversed the effect of lupeol on liver T-ICs. Using an in vivo chemoresistant HCC tumor model, lupeol dramatically decreased the tumor volumes of MHCC-LM3 HCC cell line-derived xenografts, and the effect was equivalent to that of combined cisplatin and doxorubicin treatment. Lupeol exerted a synergistic effect without any adverse effects on body weight when combined with chemotherapeutic drugs. Conclusion: Our results suggest that lupeol may be an effective dietary phytochemical that targets liver T-ICs. © 2010 American Association for the Study of Liver Diseases. | ||||
Persistent Identifier | http://hdl.handle.net/10722/148634 | ||||
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 | ||||
ISI Accession Number ID |
Funding Information: Supported by the Hong Kong Research Grants Council Collaborative Research Fund (HKU 1/06C and HKU 7/CRF/09). I. O. L. Ng is Loke Yew Professor in Pathology. | ||||
References | |||||
Grants |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, TKW | en_US |
dc.contributor.author | Castilho, A | en_US |
dc.contributor.author | Cheung, VCH | en_US |
dc.contributor.author | Tang, KH | en_US |
dc.contributor.author | Ma, S | en_US |
dc.contributor.author | Ng, IOL | en_US |
dc.date.accessioned | 2012-05-29T06:14:14Z | - |
dc.date.available | 2012-05-29T06:14:14Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Hepatology, 2011, v. 53 n. 1, p. 160-170 | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/148634 | - |
dc.description.abstract | Liver tumor-initiating cells (T-ICs) are capable of self-renewal and tumor initiation and are more chemoresistant to chemotherapeutic drugs. The current therapeutic strategies for targeting stem cell self-renewal pathways therefore represent rational approaches for cancer prevention and treatment. In the present study, we found that Lup-20(29)-en-3β-ol (lupeol), a triterpene found in fruits and vegetables, inhibited the self-renewal ability of liver T-ICs present in both hepatocellular carcinoma (HCC) cell lines and clinical HCC samples, as reflected by hepatosphere formation. Furthermore, lupeol inhibited in vivo tumorigenicity in nude mice and down-regulated CD133 expression, which was previously shown to be a T-IC marker for HCC. In addition, lupeol sensitized HCC cells to chemotherapeutic agents through the phosphatase and tensin homolog (PTEN)-Akt-ABCG2 pathway. PTEN plays a crucial role in the self-renewal and chemoresistance of liver T-ICs; down-regulation of PTEN by a lentiviral-based approach reversed the effect of lupeol on liver T-ICs. Using an in vivo chemoresistant HCC tumor model, lupeol dramatically decreased the tumor volumes of MHCC-LM3 HCC cell line-derived xenografts, and the effect was equivalent to that of combined cisplatin and doxorubicin treatment. Lupeol exerted a synergistic effect without any adverse effects on body weight when combined with chemotherapeutic drugs. Conclusion: Our results suggest that lupeol may be an effective dietary phytochemical that targets liver T-ICs. © 2010 American Association for the Study of Liver Diseases. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | en_US |
dc.relation.ispartof | Hepatology | en_US |
dc.rights | Hepatology. Copyright © John Wiley & Sons, Inc. | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antigens, Cd | en_US |
dc.subject.mesh | Carcinoma, Hepatocellular - Drug Therapy | en_US |
dc.subject.mesh | Cell Division - Drug Effects | en_US |
dc.subject.mesh | Drug Resistance, Neoplasm | en_US |
dc.subject.mesh | Glycoproteins | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver Neoplasms - Drug Therapy | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Neoplasm Transplantation | en_US |
dc.subject.mesh | Pten Phosphohydrolase - Physiology | en_US |
dc.subject.mesh | Pentacyclic Triterpenes - Therapeutic Use | en_US |
dc.subject.mesh | Peptides | en_US |
dc.title | Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lee, TKW:tkwlee@hkucc.hku.hk | en_US |
dc.identifier.email | Ma, S:sma@pathology.hku.hk | en_US |
dc.identifier.email | Ng, IOL:iolng@hkucc.hku.hk | en_US |
dc.identifier.authority | Lee, TKW=rp00447 | en_US |
dc.identifier.authority | Ma, S=rp00506 | en_US |
dc.identifier.authority | Ng, IOL=rp00335 | en_US |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.doi | 10.1002/hep.24000 | en_US |
dc.identifier.pmid | 20979057 | - |
dc.identifier.scopus | eid_2-s2.0-78751552761 | en_US |
dc.identifier.hkuros | 189789 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-78751552761&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 53 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 160 | en_US |
dc.identifier.epage | 170 | en_US |
dc.identifier.eissn | 1527-3350 | - |
dc.identifier.isi | WOS:000286406300018 | - |
dc.publisher.place | United States | en_US |
dc.relation.project | Molecular pathology of liver cancer - a multidisciplinary study | - |
dc.relation.project | Molecular Pathology of Liver Cancer - a Multidisciplinary Study | - |
dc.identifier.issnl | 0270-9139 | - |